$BLLN

Atay Oguzhan sold $3.2M of BLLN

Atay Oguzhan (Chairman and CEO) sold 26,250 shares of BillionToOne, Inc. (BLLN) at an average of $122.05 ($118.49–$124.61, $3.20M total) across 14 trades on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Jul 8, 2026, 11:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 8, 2026, 11:11 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale size, price range, and post-transaction holdings (0 shares) by the CEO/Chairman under a 10b5-1 plan.

02

Market read

Traders may monitor for sentiment/positioning effects, but there is no accompanying fundamental catalyst in the filing.

03

What to watch

The CEO ended with 0 shares, which can be interpreted as a stronger sentiment signal than typical partial sales, even if the plan was pre-arranged.

Relevance 5/10Novelty 5/10Timing: Filed after-hours on 2026-07-08, reflecting trades dated 2026-07-06.

Background

The article is an SEC Form 4 insider transaction disclosure for BillionToOne, Inc. (BLLN).

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

BillionToOne CEO/Chairman Atay Oguzhan sold 26,250 shares in open-market trades totaling about $3.2M, leaving 0 shares.

Expected impact

Likely limited immediate price impact; any effect is more sentiment/flow related than fundamentals.

Evidence & confidence

The filing is a primary Form 4 disclosure with a stated pre-arranged 10b5-1 plan, and it does not include new operating or guidance information.

Market effects

Minimal sector read-through; this is company-specific insider activity without new clinical, regulatory, or commercial datapoints.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can be purely planned liquidity, so the market may overreact if it treats it as a signal of deteriorating fundamentals.

Key entities

  • BillionToOne, Inc.

    Subject of the Form 4 insider sale disclosure.

  • Atay Oguzhan

    Chairman and CEO who executed the open-market sale under a 10b5-1 plan.

Related articles

$BLLNMedAI 8/10

BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the Move - BillionToOne (NASDAQ:BLLN)

BillionToOne (NASDAQ:BLLN) shares fell 28.12% in after-hours after reporting Q2 results. For the quarter ended June 30, 2026, revenue rose to $109.4M from $66.6M, net income was $8.1M ($0.15/share), and gross margin improved to 70%. The company kept 2026 revenue guidance of $450M to $465M and plans Unity Fetal Risk Screen (Aug. 17) and Northstar Origin (Sept. 1) launches.

$BLLNMedAI 8/10

Billiontoone (BLLN) – Research Analysts’ Recent Ratings Updates

BillionToOne (NASDAQ: BLLN) saw multiple analyst rating and target changes. Weiss Ratings upgraded BLLN to “sell (d+)” (from “sell (d)”) on 5/15 and reaffirmed “sell (d)” on 5/1. Guggenheim raised its target to $120 (from $100) and kept a “buy” on 5/13. JPMorgan lifted its target to $125 and maintained “overweight” on 5/7. BTIG cut its target to $130 (from $140) while keeping “buy” on 5/7.